Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascend-7: Ceritinib in ALK+ NSCLC with Brain or Leptomeningeal Metastases
NCT02336451Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02336451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336451.